Product Description: Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis)[1][2][3][4].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C9H22NNaO7P2
References: [1]Journe F, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8(1):R2./[2]Thaler R, et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol. 2013 Jan 15;85(2):173-85./[3]Pfister T, et al. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003 Sep 30;191(2-3):159-67./[4]Russell RG. Ibandronate: pharmacology and preclinical studies. Bone. 2006 Apr;38(4 Suppl 1):S7-12.
CAS Number: 138844-81-2
Molecular Weight: 341.21
Research Area: Metabolic Disease; Cancer
Solubility: 10 mM in H2O
Target: Apoptosis
Deutsch
English
